Biomarkers in localized prostate cancer

被引：41

作者：

Ferro, Matteo ^{[1
]}

Buonerba, Carlo ^{[2
]}

Terracciano, Daniela ^{[3
]}

Lucarelli, Giuseppe ^{[4
]}

Cosimato, Vincenzo ^{[3
]}

Bottero, Danilo ^{[1
]}

Deliu, Victor M. ^{[1
]}

Ditonno, Pasquale ^{[4
]}

Perdona, Sisto ^{[5
]}

Autorino, Riccardo ^{[6
]}

Coman, Ioman ^{[7
]}

De Placido, Sabino ^{[2
]}

Di Lorenzo, Giuseppe ^{[2
]}

De Cobelli, Ottavio ^{[1
,7
]}

机构：

[1] European Inst Oncol, Div Oncol, Milan, Italy

[2] Univ Naples Federico II, Dept Clin Med & Surg, Med Oncol, Naples, Italy

[3] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy

[4] Univ Bari, Dept Emergency & Organ Transplantat Urol, Androl & Kidney Transplantat Unit, Bari, Italy

[5] Natl Canc Inst, Dept Urol, Naples, Italy

[6] Univ Hosp Case Med Ctr, Inst Urol, Cleveland, OH 44106 USA

[7] Univ Med & Pharm, Dept Urol Iuliu Hatieganu, Cluj Napoca 400012, Romania

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 03期

关键词：

biomarkers; prostate cancer; HEALTH INDEX PHI; ANTIGEN VELOCITY; ACTIVE SURVEILLANCE; KALLIKREIN MARKERS; SERUM SARCOSINE; BIOPSY RECLASSIFICATION; RADICAL PROSTATECTOMY; PROGNOSTIC VALUE; PRECURSOR FORM; RISK;

D O I：

10.2217/fon.15.318

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biomarkers can improve prostate cancer diagnosis and treatment. Accuracy of prostate-specific antigen (PSA) for early diagnosis of prostate cancer is not satisfactory, as it is an organ-but not cancer-specific biomarker, and it can be improved by using models that incorporate PSA along with other test results, such as prostate cancer antigen 3, the molecular forms of PSA (proPSA, benign PSA and intact PSA), as well as kallikreins. Recent reports suggest that new tools may be provided by metabolomic studies as shown by preliminary data on sarcosine. Additional molecular biomarkers have been identified by the use of genomics, proteomics and metabolomics. We review the most relevant biomarkers for early diagnosis and management of localized prostate cancer.

引用

页码：399 / 411

页数：13

共 50 条

[1] Clinical Utility of Biomarkers in Localized Prostate Cancer
Leapman, Michael S.
Nguyen, Hao G.
Cooperberg, Matthew R.
[J]. CURRENT ONCOLOGY REPORTS, 2016, 18 (05)
[2] Clinical Utility of Biomarkers in Localized Prostate Cancer
Michael S. Leapman
Hao G. Nguyen
Matthew R. Cooperberg
[J]. Current Oncology Reports, 2016, 18
[3] Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
Eggener, Scott E.
Rumble, R. Bryan
Armstrong, Andrew J.
Morgan, Todd M.
Crispino, Tony
Cornford, Philip
van der Kwast, Theodorus
Grignon, David J.
Rai, Alex J.
Agarwal, Neeraj
Klein, Eric A.
Den, Robert B.
Beltran, Himisha
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (13) : 1474 - +
[4] New biomarkers for diagnosis and prognosis of localized prostate cancer
Chistiakov, Dimitry A.
Myasoedova, Veronika A.
Grechko, Andrey V.
Melnichenko, Alexandra A.
Orekhov, Alexander N.
[J]. SEMINARS IN CANCER BIOLOGY, 2018, 52 : 9 - 16
[5] Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer
Moul, Judd W.
[J]. EUROPEAN UROLOGY FOCUS, 2022, 8 (03): : 641 - 642
[6] Molecular biomarkers to guide precision medicine in localized prostate cancer
Smits, Minke
Mehra, Niven
Sedelaar, Michiel
Gerritsen, Winald
Schalken, Jack A.
[J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2017, 17 (08) : 791 - 804
[7] Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy
Hall, William A.
Lawton, Colleen A.
Jani, Ashesh B.
Pollack, Alan
Feng, Felix Y.
[J]. SEMINARS IN RADIATION ONCOLOGY, 2017, 27 (01) : 11 - 20
[8] Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary
Eggener, Scott E.
Rumble, R. Bryan
Beltran, Himisha
[J]. JCO ONCOLOGY PRACTICE, 2020, 16 (06) : 340 - +
[9] The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.
Brastianos, Harry
Murgic, Jure
Salcedo, Adriana
Chua, Melvin Lee Kiang
Meng, Alice
Fraser, Michael
Brundage, Michael Donald
Fleshner, Neil Eric
van der Kwast, Theodorus
Bristow, Robert G.
Boutros, Paul Christopher
Berlin, Alejandro
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[10] DETERMINATION OF THE IMPACT OF INTRATUMOURAL HETEROGENEITY ON PROGNOSTIC BIOMARKERS IN LOCALIZED PROSTATE CANCER
Brastianos, Harry
Murgic, Jure
Salcedo, Adriana
Chua, Melvin
Meng, Alice
Fraser, Michael
Brundage, Michael
Fleshner, Neil
van der Kwast, Theodorus
Bristow, Robert
[J]. RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S19 - S20

← 1 2 3 4 5 →